In addition, other genes that did not reach statistical significance when analyzed individually for OS impact, due to the limited number of mutated patients for the specific gene assessed (i.e., patients with JAK3 and JAK1 mutations), could also impair the selection of a very low-risk group of patients.
← all excerpts
Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials.
1
—
—